When Gonorrhea Spreads Through the Blood: Alaska's Surge in Disseminated Gonococcal Infection, 2023–2024

Disseminated gonococcal infection (DGI) is a rare but serious complication of gonorrhea, occurring in fewer than 1% of reported cases. It happens when Neisseria gonorrhoeae gets into the bloodstream and spreads from where it started — the genital tract, throat or rectum — to other parts of the body. It can cause septic arthritis, skin lesions, pain in several joints, and inflammation of tendon sheaths; rarely, endocarditis, meningitis or death. A study of 274 cases in 13 states in 2020–2022 found 2.2% died.

An alarm in Anchorage

In April 2024, an infectious disease physician told the Alaska Section of Epidemiology (SOE) about a rise in suspected DGI among patients coming to Anchorage emergency departments with joint pain. State data showed a sustained rise since July 2023. SOE stepped up surveillance and reviewed every likely or verified case reported in 2023–2024.

A verified case had the bacteria found at a disseminated site — skin, joint fluid, blood or spinal fluid; a likely case had compatible symptoms with no other cause and the bacteria found only at a mucosal site.

Likely and verified DGI cases by month reported, Alaska, June 2022–December 2024. CDC

The 35 patients

Symptoms: septic arthritis (60%), fever (37%), pain in several joints (34%); three developed endocarditis.

Outcomes: 89% were hospitalized; 20 (57%) needed surgery — 18 joint aspirations, washouts or debridements and two heart valve replacements. 83% completed the recommended treatment, intravenous ceftriaxone; six left against medical advice or were lost to follow-up. No deaths were reported among these cases. Of the 25 patients tested at a genital or urinary site, 15 (60%) were positive.

The bacteria

CDC tested 18 isolates from disseminated sites collected in 2020–2024 (14 from 2023–2024 cases) for antibiotic susceptibility and sequenced their genomes.

• Good news: all were susceptible to ceftriaxone — the first-line treatment — and to cefixime.
• Resistance elsewhere: several showed high-level resistance to penicillin and tetracycline, and 13 carried markers of ciprofloxacin resistance.
• A virulence marker: 13 isolates (72%) carried the porB1A allele, linked to dissemination — against fewer than 1% (1 of 110) of comparison isolates from uncomplicated genital infections in and around Anchorage.
• A new strain: 8 (44%) isolates, collected December 2023–April 2024, shared a sequence type — MLST-18036 — never before reported in the United States. All carried porB1A, all were highly tetracycline-resistant, and they formed a tight genetic cluster (an average of fewer than 7 SNPs apart).
• None of the DGI isolates was closely related to the genital isolates collected in 2023–2024.

Why it matters

The steady rise and the close genetic relatedness point to a more virulent strain circulating in Alaska. As in recent DGI investigations in California and Michigan, many patients had no mucosal symptoms and weren't in groups routinely screened for gonorrhea (such as sexually active women under 25), which makes diagnosis easy to delay or miss. Gonorrhea of the throat — often symptomless — may predispose to DGI, so testing every site of sexual exposure matters. Untreated, DGI can cause septic shock, endocarditis and death; Alaska's first known DGI death was reported in July 2025.

What Alaska did: expanded partner services in October 2024, and broadened gonorrhea screening to all sexually active patients with risk factors such as substance use, multiple partners or a history of sexually transmitted infections. Sexual networks were hard to trace, likely because of undiagnosed infections without symptoms and delays in testing.

For clinicians

• Keep DGI in mind in anyone with compatible signs — even without genital, throat or rectal symptoms — and take a detailed sexual history.
• When you suspect it, take specimens (NAAT and culture) from the suspected disseminated site and from urogenital, rectal and throat sites according to exposure; test every gonococcal isolate for antibiotic susceptibility. Collect cultures before empiric treatment where possible.
• Follow CDC's STI Treatment Guidelines; hospitalize with infectious disease consultation for initial treatment, especially in severe cases.
• Report confirmed and suspected cases promptly.

Limits

DGI is likely undercounted — diagnosis often rests on symptoms, sterile-site cultures aren't always taken or may be negative, the underlying infection may be silent, and some symptoms develop slowly. Testing was incomplete; interviews may miss sexual and drug-use history; only available isolates were tested; and interviews began late in the outbreak.

Sources

Based on Rogers JH, Ohlsen E, Stump JC, et al., "Increase in Disseminated Gonococcal Infections — Alaska, 2023–2024," MMWR volume 75, number 27, Centers for Disease Control and Prevention, with authors from CDC and the Alaska Division of Public Health; a work of the United States government in the public domain.